CRUSH!!MDS 

2013 Clinical Research Consortium American Society of Hematology Abstracts

1. 264 - Molecular Defects In BRCC3 Complex, a Novel Pathogenic Pathway In MDS (Oral Presentation)
   Dayong Huang, MD, Hideki Makishima, MD, PhD, Yang Du, PhD, Naoko Hosono, MD, PhD, Wenyi Shen, MD, Chantana Polprasert, MD, Mikkael A. Sekeres, MD, MS, Bartlomiej Przychodzen, PhD, Richard A Padgett, PhD, Jarnail Singh, PhD, Kathryn M Guinta, Michael J. Clemente, Brittney Dienes, Manuel Afable, RN, Holleh D Husseinzadeh, MD, Sarah Mcmahon, Yogen Saunthararajah, MD, Kenichi Yoshida, MD, Yuichi Shiraishi, PhD, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Satoru Miyano, PhD, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD, FACP
   
   
2. 388 - Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure (Oral Presentation)
   Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Lianchun Xiao, Al Ali Najla, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Jeffery Bryan, Hillary Prescott, David P. Steensma, MD, Mikkael A. Sekeres, MD, MS, Gail J. Roboz, MD, Alan List, MD, Hagop M Kantarjian, MD and Rami S Komrokji, MD
   
   
3. 518 - Clinical “MUTATOME” Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia (Oral Presentation)
   Hideki Makishima, MD, PhD, Thomas LaFramboise, PhD, Bartlomiej P Przychodzen, PhD, Kenichi Yoshida, MD, Matthew Ruffalo, BS, Inés Gómez-Seguí, MD, Holleh D Husseinzadeh, MD, Yuichi Shiraishi, PhD, Masashi Sanada, MD, Yasunobu Nagata, MD, Yusuke Sato, MD, Aiko Sato-Otsubo, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Tsuyoshi Nakamaki, MD, Wolf-Karsten Hofmann, MD, Shuichi Miyawaki, MD, Lee-Yung Shih, MD, Shigeru Chiba, MD, PhD, Satoru Miyano, PhD, Naoko Hosono, MD, PhD, Chantana Polprasert, MD, Swapna Thota, MD, Brittney Dienes, Kathryn M Guinta, Yogen Saunthararajah, MD, Mikkael A. Sekeres, MD, MS, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD, FACP
   
   
4. 522 - Comprehensive Identification Of Germline Alterations In Telomerase Complex Genes By Whole Exome Sequencing Of MDS and Related Myeloid Neoplasms (Oral Presentation)
   Chantana Polprasert, MD, Mikkael A. Sekeres, MD, MS, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Naoko Hosono, MD, PhD, Richard A Padgett, PhD, Jarnail Singh, PhD, Otrock Zaher, MD, Sudipto Mukherjee, MD, PhD, MPH, Manuel G. Afable II, Holleh D Husseinzadeh, MD, Sarah Mcmahon, Wenyi Shen, MD, Dayong Huang, MD, Kenichi Yoshida, MD, Yuichi Shiraishi, PhD, Kenichi Chiba, BA, Hiroko Tanaka, BA, Satoru Miyano, PhD, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD
   
   
5. 655 - Novel Pathogenic Defects Of Dead/H-Box Helicases In Myeloid Neoplasms (Oral Presentation)
   Chantana Polprasert, MD, Mikkael A. Sekeres, MD, MS, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Naoko Hosono, MD, PhD, Richard A Padgett, PhD, Jarnail Singh, PhD, Otrock Zaher, MD, Sudipto Mukherjee, MD, PhD, MPH, Manuel G. Afable II, Holleh D Husseinzadeh, MD, Sarah Mcmahon, Wenyi Shen, MD, Dayong Huang, MD, Kenichi Yoshida, MD, Yuichi Shiraishi, PhD, Kenichi Chiba, BA, Hiroko Tanaka, BA, Satoru Miyano, PhD, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD
   
   
6. 659 - Somatic Mutational Screen For Improved Prediction Of The Outcomes Of Epigenetic Therapy In MDS (Oral Presentation)
   Swapna Thota, MD, Paul Lakin, Holleh Husseinzadeh, MD, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Brittney Dienes, Kathryn M Guinta, Naoko Hosono, MD, PhD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD, MS, Yogen Saunthararajah, MD and Jaroslaw P. Maciejewski, MD, PhD
   
   
7. 1231 - Germline Events In GFI1 In Myelodysplastic Syndrome (Poster)
   Swapna Thota, MD, Sarah McMahon, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, Kathryn M Guinta, Brittney Dienes, Naoko Hosono, MD, PhD, Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, PhD
   
   
8. 1505 - Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium (Poster)
   Rami S Komrokji, MD, Xiao-Feng Wang, PhD, Najla H Al Ali, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Gail J. Roboz, MD, Steven D Gore, Sean Hobson, Cassandra Zimmerman, Eric Padron , MD, Jaroslaw P. Maciejewski, MD, PhD, Alan List, MD and Mikkael A. Sekeres, MD, MS
   
   
9. 1566 - Clinical and Molecular Features Of Young Patients With Myelodisplastic Syndromes (MDS) (Poster)
   Bilori Bilori, MD, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Mohamed Ashkar, Rohan Garje, MD, Swapna Thota, MD, Brittney Dienes, Kathryn M Guinta, Ramon V. Tiu, MD, BS, Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, PhD
   
   
10. 2807 - Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies (Poster)
    Zaher K. Otrock, MD, Bartlomiej P Przychodzen, PhD, Holleh D Husseinzadeh, MD, Hideki Makishima, MD, PhD, Brittney Dienes, Naoko Hosono, MD, PhD, Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, PhD, FACP
    
    
11. 3560 - The Effect Of Insurance Status and Comorbidities On Outcomes After Splenectomy Among Patients With ITP (Poster)
    Gaurav Kistangari, MD, Keith R. McCrae, MD, Swapna Thota, MD, Nicholas Schiltz and Siran M Koroukian, PhD
    
    
12. 3902 - Inhibition Of The JAK/STAT Signaling Pathway As a Novel Therapy In CD8+ T-Large Granular Lymphocyte Leukemia (Poster)
    Michael J. Clemente, Bilori Bilori, Swapna Thota, MD, Manuel G. Afable II, Holleh D. Husseinzadeh, Alan E. Lichtin and Jaroslaw P. Maciejewski, MD, PhD
    
    
13. 724 - Differences In Perceptions Of Disease and Treatment Effectiveness and Adherence Between Physicians and Patients With Myelodysplastic Syndromes (MDS) (Oral Presentation)
    David P. Steensma, MD, Richard M. Stone, MD, John Huber, MS, Betsy Dennison, MS, RN and Mikkael A. Sekeres, MD, MS
    
    
14. 2510 - The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies (Poster)
    Akinori Yoda, PhD, Guillaume Adelmant, PhD, Nobuaki Shindoh, PhD, Bjoern Chapuy, MD, PhD, Yuka Yoda, MPh, Oliver Weigert, Nadja Kopp, Shuo-Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Jeffrey W. Tyner, Jason Gotlib, MD, MS, Michael W. Deininger, MD, PhD, Shannon Turley, PhD, Jarrod A Marto, PhD, Andrew A. Lane, MD, PhD and David M. Weinstock, MD
    
    
15. 1564 - Application Of The Revised IPSS (IPSS-R) and The French Prognostic Score (FPS) To Assess Overall Survival (OS) In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Azacitidine (Aza) In a Large North American Intergroup Trial (Poster)
    Amer M. Zeidan, MD, Ju-Whei Lee, Thomas Prebet, MD PhD, Peter L. Greenberg, MD, Mark B Juckett, MD, Zhouxin Sun, PhD, Mitchell R Smith, MD, PhD, Elisabeth Paietta, PhD, Janice L. Gabrilove, MD, Harry P Erba, MD, Steven D Gore and Martin S Tallman, MD
    
    
16. 2771 - The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza) (Poster)
    Amer M. Zeidan, MD, Najla H Al Ali, Mohamed A. Kharfan-Dabaja, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E Lancet, MD, Alan F List, MD and Rami S Komrokji, MD
    
    
17. 1530 - Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age (Poster)
    Naval G. Daver, MD, Kiran Naqvi, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Farhad Ravandi, MD, Aziz Nazha, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Mark Brandt, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Sherry R. Pierce, RN, BS, Elias Jabbour, MD, Jorge E. Cortes, MD and Hagop M. Kantarjian, MD
    
    
18. 1554 - Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS) (Poster)
    Guillermo Garcia-Manero, MD, Michael Savona, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Paul Conkling, MD, CL Beach, PharmD, Joel Hetzer, PhD, Qian Dong, MS and Barry S. Skikne, MD
    
    
19. 2767 - Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS) (Poster)
    Hui Yang, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Courtney D. DiNardo, MD, Marcos R Estecio, PhD, Masoud Davanlou, MD, Qi-Rong Geng, MD, Zhihong Fang, Martin Nguyen, BS, Sherry Pierce, Yue Wei, PhD, Simrit Parmar, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD and Guillermo Garcia-Manero, MD
    
    
20. 2788 - Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy (Poster)
    Aziz Nazha, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Courtney D. DiNardo, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Stefan H. Faderl, MD, Jing Ning, Wei Qiao, Farhad Ravandi, MD, Tapan M. Kadia, MD, Sherry R. Pierce, RN, BS, Jorge E. Cortes, MD and Guillermo Garcia-Manero, MD
    
    
21. 2801 - Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA) (Poster)
    Elias Jabbour, MD, Hagop M Kantarjian MD, Elias Jabbour, MD, Courtney D. DiNardo, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Stefan H. Faderl, MD, Jing Ning, Wei Qiao, Farhad Ravandi, MD, Tapan M. Kadia, MD, Sherry R. Pierce, RN, BS, Jorge E. Cortes, MD and Guillermo Garcia-Manero, MD
    
    
22. 2805 - Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS) (Poster)
    Yue Wei, PhD, Yu Jia, Hong Zheng, Hui Yang, MD, PhD, Rui Chen, PhD, Hui Wang, PhD, Xia Wang and Guillermo Garcia-Manero, MD